1-20 of 90
Anna-Maria Fink
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Clinical Trials & Observations
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivchev, Carsten Utoft Niemann, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D. Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Journal: Blood
Blood (2024) 144 (18): 1924–1935.
https://doi.org/10.1182/blood.2024024631
Published: 2024
Includes: Supplemental data
Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Clinical Trials & Observations
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2024) 144 (3): 272–282.
https://doi.org/10.1182/blood.2023022730
Published: 2024
Includes: Supplemental data
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 204.
https://doi.org/10.1182/blood-2023-188705
Published: 2023
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Doerfel, Joerg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Barbara F. Eichhorst, Michael Hallek, Kirsten Fischer, Anna Maria Fink
Journal: Blood
Blood (2023) 142 (Supplement 1): 4644.
https://doi.org/10.1182/blood-2023-185741
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Clinical Trials & Observations
Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (5): 446–459.
https://doi.org/10.1182/blood.2023019634
Published: 2023
Includes: Supplemental data
Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Anna Maria Fink, Anno Federhen, Adam Giza, Sandra Robrecht, Janina Stumpf, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael G. Kiehl, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 140 (Supplement 1): 9879–9881.
https://doi.org/10.1182/blood-2022-169956
Published: 2022
Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Moritz Furstenau, Yvonne Thus, Sandra Robrecht, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Julie M.N. Dubois, Julia Von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Michael Baumann, Thomas Noesslinger, Josien Regelink, Ellen C Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Simon Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Eric Eldering, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 842–845.
https://doi.org/10.1182/blood-2022-164786
Published: 2022
Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Eugen Tausch, Christof Schneider, Moritz Furstenau, Sandra Robrecht, Deyan Yordanov Yosifov, Daniel Mertens, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Clemens-Martin Wendtner, Eric Eldering, Karl-Anton Kreuzer, Matthias Ritgen, Anna-Maria Fink, Kirsten Fischer, Arnon P. Kater, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 839–841.
https://doi.org/10.1182/blood-2022-163775
Published: 2022
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (9): 1318–1329.
https://doi.org/10.1182/blood.2021013208
Published: 2022
Includes: Supplemental data
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data